Ovarian Cancer Midwest Focus

ocmf

The 2019 Ovarian Cancer Midwest Focus Conference will focus on basic science, translational and clinical topics on ovarian cancer and will offer sessions on emerging topics such as cancer metabolism, novel therapeutics and personalized medicine. 

 

Notice: The use of video or audio recording is prohibited at this event. 

Monday, November 4, 2019 1:00-5:00pm

Welcome and Opening Remarks

Welcome Rep. Jeanne Poppe (DFL) District: 27B

Welcome Video from U.S. Senator Tina Smith

Moderator Dr. Martina Bazzaro

1:00 – 3:00 pm:  Early Detection

1:00       MOCA’s early detection research funding and trends
Kathleen Gavin, Minnesota Ovarian Cancer Alliance (MOCA), Minneapolis, MN.

1:20       Searching for needles in a haystack:  Identification of early stage ovarian cancer protein biomarkers in a multiplex platform
Amy Skubitz, Ph.D., Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota

1:40       Abstract Presentation:Proteomic analysis of Pap test fluid: A novel source for the detection of ovarian cancer biomarkers
Kristin Boylan, Ph.D., Department of Pathology, University of Minnesota

1:55       Abstract Presentation: NFATC4 Promotes Quiescence and Chemotherapy Resistance in High Grade Serous Ovarian Carcinoma (HGSOC)
Alex Cole, Ph.D., Department of Internal Medicine and Magee-Womens Research Institute and Foundation, University of Pittsburgh

2:20       Tumor Associated Extracellular Vesicles: From Biomarkers to Cancer Pathogenesis
Andrew Godwin, Ph.D., School of Medicine, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS

3:00 – 5:00 pm: Immunotherapy

3:00       Maximizing Natural Killer cell mediated immunotherapy in ovarian cancer via cytokine stimulation and checkpoint blockade
Martin Felices, Ph.D., Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota

3:40       Expression of recombinant Fc receptors by engineered lymphocytes for targeting diverse tumor antigens
Bruce Walcheck, Ph.D., Department of Veterinary and Biomedical Sciences, University of Minnesota.

4:20       Abstract Presentation: Microfluidic Organoid Cultures for Personalized Treatment of Cancer
Neda Dadgar, Department of Physiology & Biomedical Engineering, Mayo Clinic, Rochester, MN.

4:40       Immune based therapies for Ovarian cancer
Melissa Geller, M.D., M.S., Department of Obstetrics, Gynecology and Women’s Health, Division of Gynecologic Oncology, University of Minnesota

5:00 - 6:00     Reception and Hors d’oeuvres – Open for all conference attendees.

Tuesday, November 5, 2019, 7:15am-5:00pm

November 5th, 7:15 am - 1:00 pm

7:15       Breakfast Buffet

Moderator Dr. Ilana Chefetz

Welcome letter from Sen. Amy Klobuchar

8:00 – 10:00 am: Novel Therapeutics

8:00       Dozens of new cancer drugs do little to improve survival
Ilana Chefetz, Ph.D., Cancer Stem Cells & Necroptosis, Hormel Institute, University of Minnesota, Austin, MN

8:20       Microtubules stability and chemoresistance: therapeutic implications
Martina Bazzaro, Ph.D., Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota

9:00       Abstract Presentation: Proteome-level predictors of response to PARP inhibitor treatment in ovarian cancer
Stefani Thomas, Ph.D., Department of Laboratory Medicine and Pathology, University of Minnesota

9:15       Abstract Presentation: Identifying Determinants to PARPi Combination Therapies in Ovarian Cancer
Annapoorna Venkatachalam, Department of Molecular Pharmacology and Experimental Therapeutics, Oncology Research and Hematology, Mayo Clinic

9:30       Practical Components for Early Phase Discovery
William Bradley, M.D., Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI.

10:00 am – 12:00 pm: Metabolism

10:00     Overview on ovarian cancer metabolism
Xiaonan Zhang, Ph.D., Department of Oncology and Cancer Biology, Karolinska Institutet, University of Solna, Stockholm, Sweden

10:30     Oxidative Phosphorylation: a target for therapeutic strategies
Ilana Chefetz, Ph.D., Cancer Stem Cells & Necroptosis, Hormel Institute, University of Minnesota

11:00     Abstract Presentation: Implementation of a 3D Organotypic Model of the Human Mesothelium for HighThroughput Screening
Hilary A. Kenny, Ph.D., Department of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago

11:30     Abstract Presentation: The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer
Reuben S. Harris, Ph.D., Department of Biochemistry, Molecular Biology and Biophysics, College of Biological Sciences, University of Minnesota

11:45     Lunch and Panel Discussion with featured panelists: Kathleen Gavin, MOCA; Kathy Pohland, Ovarian Cancer Survivor; Dr. Melissa Geller, Gynecologic Oncologist; Stefanie Gliniany, Community Support Program Manager, MOCA

 

November 5th, 1:00 – 5:00 pm

Moderator Dr. Melissa Geller

1:00 – 3:00 pm: Preclinical Modes of Ovarian Cancer

1:00       History and role of Progesterone Receptor signaling in ovarian cancer models
Carol Lange, Ph.D., Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota

1:20       Progesterone receptor signaling drives DREAM-mediated quiescence and cancer cell phenotypes in models of early HGSC
Laura Mauro, Ph.D., Department of Animal Science, University of Minnesota.

1:40       Ovarian and fallopian tube communication in high grade serous ovarian cancer
Joanna Burdette, Ph.D., College of Pharmacy, University of Illinois, Chicago, IL.

2:20       Ovarian Cancer PDX Models in Preclinical and Clinical Studies
John Weroha, M.D., Ph.D., Department of Oncology, Mayo Clinic

3:00 – 5:00 pm: Personalized Medicine

3:00       On the Road to Precision Medicine in Ovarian Cancer
Boris Winterhoff, M.D., Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota

3:20       Probing the molecular genetics of ovarian cancer at the single cell level
Tim Starr, Ph.D., Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota

4:00       Abstract Presentation: Bridging the Gap: Tumor-Stroma Proportion and Tunneling Nanotubes as Biomarkers of Chemoresistance in the Ovarian Tumor Microenvironment
Emil Lou, M.D., Ph.D., FACP, Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota

4:20       Abstract Presentation: Dissecting intratumoral heterogeneity in ovarian cancer
Alexandre Gaspar Maia, Ph.D., Department of Pharmacology, Mayo Clinic

4:40       Where We Need to be in 10 Years: A Challenge for the Decade Ahead
Scott Kaufmann, M.D., Ph.D., Department of Oncology, Mayo Clinic

 

Thank You in advance for attending the Ovarian Cancer Midwest Focus Conference